COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Clinical Research in ALS Study (CRiALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00136500
Recruitment Status : Recruiting
First Posted : August 29, 2005
Last Update Posted : May 21, 2020
ALS Association
ALS Recovery Fund
Information provided by (Responsible Party):
Michael Benatar, University of Miami

Brief Summary:
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).

Condition or disease
Amyotrophic Lateral Sclerosis

Detailed Description:
Research goals include elucidation of the complex relationship between ALS and related neurodegenerative disorders, development of both wet and dry biomarkers of disease, and delineation of the full course of the natural history of disease from the early pre-symptomatic stages through established and even late-stage disease. These goals are accomplished through the recruitment and evaluation of patients with ALS and related diseases, family members (including people at genetic risk for ALS, but who are not yet affected), and healthy controls.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Clinical Research in Amyotrophic Lateral Sclerosis
Study Start Date : February 2005
Estimated Primary Completion Date : December 2027
Estimated Study Completion Date : December 2027

Primary Outcome Measures :
  1. Recruitment [ Time Frame: Annually ]
    Since this is an umbrella/gateway protocol through which individuals are recruited to participate in a range of studies, outcome is assessed in terms of recruitment.

Biospecimen Retention:   Samples With DNA
DNA, blood, urine, CSF, skin biopsies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The CRiALS research program aims to recruit three types of participants:

  • Individuals affected with ALS or a related neurodegenerative disease
  • Unaffected individuals from pedigrees in which the genetic cause of ALS is known
  • Healthy controls

Inclusion Criteria:

  1. At least 18 years of age.
  2. Member of at least one of the following categories:

    1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial)
    2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases.
    3. Healthy controls
  3. Able and willing to comply with relevant procedures.

Exclusion Criteria:

Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00136500

Layout table for location contacts
Contact: Anne-Laure Grignon, MD 888-413-9315
Contact: Danielle Dauphin 888-413-9315

Layout table for location information
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Anne-Laure Grignon, MD    888-413-9315   
Sponsors and Collaborators
Michael Benatar
ALS Association
ALS Recovery Fund
Layout table for investigator information
Principal Investigator: Michael Benatar, MD, PhD. University of Miami
Additional Information:
Layout table for additonal information
Responsible Party: Michael Benatar, MBChB, MS, DPhil, University of Miami Identifier: NCT00136500    
Other Study ID Numbers: FALS feasibility
First Posted: August 29, 2005    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: May 2020
Keywords provided by Michael Benatar, University of Miami:
natural history
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases